Akamatsu H, Koh Y, Nishio M, Goto Y, et al. Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancer. Lung Cancer 2024;198:108017.
PMID: 39571250